Clinical Trial Update: Virus DNX2401 and Temozolomide in Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

Clinical trial update reporting on a Phase 1 study of DNX-2401 in combination with temozolomide for recurrent glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• DNX-2401 (Delta-24-RGD)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra | Conditions: Glioblastoma Multiforme, Recurrent Tumor | Phase 1 | Status: COMPLETED